Buy this Article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, RN

Abstract

* Epclusa, an oral, fixed-dose combination drug containing sofosbuvir and velpatasvir, is the first agent approved to treat all six variants of the hepatitis C genotype. * It is prescribed as monotherapy if the patient has compensated (mild) cirrhosis or no cirrhosis and as combination therapy with ribavirin if the patient has decompensated cirrhosis.